Skip to main navigation
Skip to search
Skip to main content
Monash University Home
Help & FAQ
Home
Profiles
Research units
Equipment
Projects
Outputs
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
A Phase 1, Dose Escalation Study of Flotetuzumab, a CD123 x CD3 DART Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Wei, Andrew
(Primary Chief Investigator (PCI))
Kennedy, Nola
(Project Manager)
Australian Centre for Blood Diseases
Project
:
Research
Overview
Project Details
Status
Active
Effective start/end date
9/07/19
→
31/12/24
View all
View less
Keywords
Malignant Haematology
Acute Myeloid Leukemia
Clinical trial